A new ScienceDirect article published yesterday put ketogenic therapy squarely in the treatment conversation for developmental and epileptic encephalopathy with spike-wave activation in sleep, or DEE-SWAS. The paper focused on neurodevelopmental risk factors and the comparative effects of ketogenic treatment, steroids and benzodiazepines, underscoring that this is therapeutic keto for a severe pediatric epilepsy syndrome, not lifestyle keto for general wellness.
DEE-SWAS is a rare but serious childhood-onset epilepsy syndrome marked by sleep-potentiated epileptiform activity, seizures and developmental stagnation or regression that can affect cognition, language and behavior. The new analysis says seizure frequency is a critical modifiable predictor of neurodevelopmental impairment and relapse, independent of the overall SWAS burden, while structural etiology raises the risk of cognitive impairment. That fits with a 2024 Annals of Neurology etiology study and a 2025 review showing the disorder remains poorly understood despite being described for more than half a century.
On treatment, the article found ketogenic diet therapy reduced the spike-wave index, with an effect described as comparable to steroids and benzodiazepines and no statistically significant between-group difference in the summary. It also pointed to high-dose diazepam as a promising option in refractory cases. For families and clinicians, that places ketogenic therapy in the same serious clinical lane as established drug treatment, rather than as a fringe add-on or a general wellness diet.
The broader evidence base gives that comparison real weight. The RESCUE ESES trial, a multicenter randomized controlled trial at eight tertiary referral centers in seven European countries, enrolled children ages 2 to 12 who were diagnosed within six months and had not previously been treated with corticosteroids or clobazam. In that study, corticosteroids produced better cognitive outcomes at six months than clobazam, while the background emphasized that both drugs had long been viewed as leading options for this sleep-activated epilepsy.
Newer ketogenic work is now pushing the diet deeper into that same clinical discussion. A 2025 prospective study of the modified Atkins diet in children with D/EE-SWAS said the role of ketogenic therapy remains inadequately studied, while variants such as modified Atkins and low glycemic index treatment are already used in epilepsy care to improve flexibility and adherence. The message from the newest article is straightforward: when DEE-SWAS threatens development, the keto in question is a closely supervised medical therapy built to protect the brain.
Every story on Keto Diet Magazine is assembled by an automated editorial system that works from verified research, official records, and credible reporting, then clears automated accuracy and moderation checks before it goes live. The standards that system follows are set and overseen by the people who run the publication. Read our full editorial policy.
Did this article answer your question?
